Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5508-LBA5508
Author(s):  
S. Pignata ◽  
G. Scambia ◽  
A. Savarese ◽  
R. Sorio ◽  
E. Breda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Multicenter Trial ◽  
Final Text ◽  
Financial Relationships

LBA5508 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5509-LBA5509
Author(s):  
E. Pujade-Lauraine ◽  
S. Mahner ◽  
J. Kaern ◽  
V. Gebski ◽  
M. Heywood ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Gynecologic Cancer ◽  
Pegylated Liposomal Doxorubicin ◽  
Phase Iii ◽  
Platinum Sensitive ◽  
Phase Iii Study ◽  
Final Text

LBA5509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1-1
Author(s):  
G. J. Rustin ◽  
M. E. van der Burg
Keyword(s):  
Ovarian Cancer ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Treatment ◽  
Clinical Indicators ◽  
Delayed Treatment ◽  
Ca125 Level ◽  
Final Text ◽  
Financial Relationships

1 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA9084-LBA9084
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Field Control ◽  
Melanoma Patients ◽  
Final Text ◽  
Financial Relationships

LBA9084 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA509-CRA509
Author(s):  
V. Dezentje ◽  
N. J. Van Blijderveen ◽  
H. Gelderblom ◽  
H. Putter ◽  
M. P. Van Herk-Sukel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Pharmacoepidemiological Study ◽  
Final Text ◽  
Financial Relationships

CRA509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4-LBA4 ◽  
Author(s):  
N. Wolmark ◽  
G. Yothers ◽  
M. J. O'Connell ◽  
S. Sharif ◽  
J. N. Atkins ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon ◽  
Final Text ◽  
Financial Relationships

LBA4 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA8500-LBA8500 ◽  
Author(s):  
Axel Hauschild ◽  
Jean Jacques Grob ◽  
Lev V. Demidov ◽  
Thomas Jouary ◽  
Ralf Gutzmer ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Kinase Inhibitor ◽  
Multicenter Trial ◽  
Phase Iii ◽  
Open Label ◽  
Daily News ◽  
Online Supplement ◽  
Final Text

LBA8500^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA4000-LBA4000 ◽  
Author(s):  
Tom Samuel Waddell ◽  
Ian Chau ◽  
Yolanda Barbachano ◽  
David Gonzalez de Castro ◽  
Andrew Wotherspoon ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Multicenter Trial ◽  
Daily News ◽  
Online Supplement ◽  
Esophagogastric Cancer ◽  
Final Text

LBA4000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document